FR1550956A - - Google Patents

Info

Publication number
FR1550956A
FR1550956A FR1550956DA FR1550956A FR 1550956 A FR1550956 A FR 1550956A FR 1550956D A FR1550956D A FR 1550956DA FR 1550956 A FR1550956 A FR 1550956A
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of FR1550956A publication Critical patent/FR1550956A/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
FR1550956D 1964-07-20 1965-07-20 Expired FR1550956A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US383910A US3320124A (en) 1964-07-20 1964-07-20 Method for treating coccidiosis with quinazolinones

Publications (1)

Publication Number Publication Date
FR1550956A true FR1550956A (fr) 1968-12-27

Family

ID=23515259

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1550956D Expired FR1550956A (fr) 1964-07-20 1965-07-20

Country Status (7)

Country Link
US (1) US3320124A (fr)
BR (1) BR6571429D0 (fr)
DE (1) DE1545551B2 (fr)
ES (1) ES315612A1 (fr)
FR (1) FR1550956A (fr)
GB (1) GB1087015A (fr)
IL (1) IL23717A (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2703652A1 (de) * 1976-01-29 1977-08-04 Roussel Uclaf Neues chinazolinon und dessen salze, deren herstellungsverfahren und diese enthaltende pharmazeutische zusammensetzungen
EP0027768A1 (fr) * 1979-10-23 1981-04-29 Roussel-Uclaf Nouvelles résines échangeuses d'ions du type acide, leur préparation, leur application comme médicaments et les compositions les renfermant
FR2467630A1 (fr) * 1979-10-23 1981-04-30 Roussel Uclaf Nouvelles resines echangeuses d'ions du type acide, leur procede de preparation et leur application comme medicament
FR2468368A1 (fr) * 1979-08-23 1981-05-08 Hoechst Ag Agent pour le traitement de theilerioses a base de quinazolinone
EP0794780A1 (fr) * 1994-12-22 1997-09-17 Davidson, M. Clifford Compositions pharmaceutiques contenant de la quinazolinone et leurs procedes d'utilisation

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725599A (en) * 1986-09-08 1988-02-16 Pfizer Inc. Heterocyclic ring fused pyrimidine-4 (3H)-ones as anticoccidial agents
US4797486A (en) * 1986-09-08 1989-01-10 Pfizer Inc. Heterocyclic ring fused pyrimidine-4(3H)-ones as anticoccidial agents
US5314700A (en) * 1991-01-28 1994-05-24 Ethyl Corporation Poultry feed component
CA2113229C (fr) * 1994-01-11 1999-04-20 Mark Pines Compositions anti-fibreuses contenant de la quinazolinone et methodes d'utilisation correspondantes
IL110831A (en) * 1994-08-31 1998-12-27 Hadasit Med Res Service Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis
US6090814A (en) * 1995-08-15 2000-07-18 Agricultural Research Organization Ministry Of Agriculture Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization
IL114951A (en) * 1995-08-15 1999-08-17 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization
DE69714281T2 (de) * 1996-08-30 2003-02-27 Agricultural Res Org Intracoronarer stent der quinazolinone derivate enthält
US6028075A (en) 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
EP1014988A2 (fr) * 1997-05-23 2000-07-05 Hadasit Medical Research Services & Development Co., Ltd. Traitement de la cirrhose hepatique
US6562829B1 (en) 1997-05-23 2003-05-13 Hadasit Medical Research Services & Development Co., Ltd. Treatment of hepatic cirrhosis
US6159488A (en) * 1997-08-14 2000-12-12 Agricultural Research Org. Ministry Of Agriculture (Gov.) Intracoronary stents containing quinazolinone derivatives
AU756437B2 (en) * 1998-08-13 2003-01-16 Agricultural Research Organization, Ministry Of Agricultural, State Of Israel Inhibition of pathogenic processes related to tissue trauma
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
IL143366A0 (en) * 2001-05-24 2002-04-21 Harasit Medical Res Services & Treatment of renal fibrosis
AU2002346471A1 (en) * 2001-11-20 2003-06-10 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
IL147416A (en) * 2001-12-31 2008-11-26 Israel State Combined modalities for improved cancer treatment
AU2003213092A1 (en) * 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
IL148292A (en) * 2002-02-21 2008-08-07 Shai Yarkoni Stable preparations of lupoginone and other quinazolinone derivatives
US7214800B2 (en) * 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
RU2004135554A (ru) * 2002-05-09 2006-01-20 Цитокинетикс, Инк. (Us) Пиримидиноны, композиции на их основе и способы их использования
AU2003265242A1 (en) * 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
EP1556357A4 (fr) * 2002-06-14 2006-09-13 Cytokinetics Inc Composes, compositions et procedes
WO2004009036A2 (fr) * 2002-07-23 2004-01-29 Cytokinetics, Inc. Composes, compositions et procedes
JP2005536553A (ja) * 2002-08-21 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
AU2003277079A1 (en) * 2002-09-30 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
WO2005041888A2 (fr) * 2003-11-03 2005-05-12 Cytokinetics, Inc. Composes, compositions et methodes
EP1680420A4 (fr) * 2003-11-07 2008-09-24 Cytokinetics Inc Composes, compositions et methodes
JP2007513154A (ja) * 2003-12-08 2007-05-24 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
CN1304391C (zh) * 2004-02-06 2007-03-14 上海因诺生化科技有限公司 氢溴酸常山酮的制备方法
CA2600046A1 (fr) * 2005-02-23 2006-08-31 Collgard Biopharmaceuticals Ltd. Composition pharmaceutique d'enantiomeres d isoles de derives de quinazolinone halofuginone
AU2007238816B2 (en) * 2006-04-10 2012-12-06 President And Fellows Of Harvard College Methods for modulating formation and progression of cellulite
US8754107B2 (en) * 2006-11-17 2014-06-17 Abbvie Inc. Aminopyrrolidines as chemokine receptor antagonists
AU2008206643B2 (en) 2007-01-21 2013-09-19 Agricultural Research Organization Composition and method for treating or preventing skeletal muscle fibrosis
US20090123389A1 (en) * 2007-08-15 2009-05-14 Malcolm Whitman Methods for modulating Th17 cell development in the treatment and prevention of cellulite
WO2009023267A2 (fr) * 2007-08-15 2009-02-19 President And Fellows Of Harvard College Procédé de modulation du développement et de l'expansion de cellules exprimant il-17
FR2922451A1 (fr) * 2007-10-23 2009-04-24 Windgan Trading Traitement des retrecissements de l'uretre
CA2737219C (fr) * 2008-08-11 2017-02-28 Tracy Keller Analogues d'halofuginone pour l'inhibition d'arnt synthetases et leurs utilisations
US8357692B2 (en) 2010-06-20 2013-01-22 Washington University Methods of treatment of bone degenerative diseases
CA2861840C (fr) 2012-01-13 2020-12-15 President And Fellows Of Harvard College Derives d'halofuginol et leur utilisation dans des compositions cosmetiques et pharmaceutiques
WO2019237125A1 (fr) 2018-06-08 2019-12-12 The General Hospital Corporation Inhibiteurs de la prolyl-arnt-synthétase
CN111233831A (zh) * 2020-03-18 2020-06-05 郑州市华农兽药研究院 常山铜琥珀酸单酯及其制备方法与用途
CN112409272A (zh) * 2020-11-26 2021-02-26 河北美荷药业有限公司 一种6-氯-7-溴-4（3h）-喹唑啉酮的制备方法和应用

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2703652A1 (de) * 1976-01-29 1977-08-04 Roussel Uclaf Neues chinazolinon und dessen salze, deren herstellungsverfahren und diese enthaltende pharmazeutische zusammensetzungen
FR2468368A1 (fr) * 1979-08-23 1981-05-08 Hoechst Ag Agent pour le traitement de theilerioses a base de quinazolinone
EP0027768A1 (fr) * 1979-10-23 1981-04-29 Roussel-Uclaf Nouvelles résines échangeuses d'ions du type acide, leur préparation, leur application comme médicaments et les compositions les renfermant
FR2467630A1 (fr) * 1979-10-23 1981-04-30 Roussel Uclaf Nouvelles resines echangeuses d'ions du type acide, leur procede de preparation et leur application comme medicament
EP0794780A1 (fr) * 1994-12-22 1997-09-17 Davidson, M. Clifford Compositions pharmaceutiques contenant de la quinazolinone et leurs procedes d'utilisation
EP0794780A4 (fr) * 1994-12-22 1997-11-12 Davidson M Clifford Compositions pharmaceutiques contenant de la quinazolinone et leurs procedes d'utilisation

Also Published As

Publication number Publication date
DE1545551A1 (de) 1969-10-16
ES315612A1 (es) 1966-07-01
IL23717A (en) 1971-01-28
US3320124A (en) 1967-05-16
BR6571429D0 (pt) 1973-08-14
DE1545551B2 (de) 1976-12-23
GB1087015A (en) 1967-10-11

Similar Documents

Publication Publication Date Title
FR1550956A (fr)
AU442366B2 (fr)
BE621510A (fr)
BE642588A (fr)
BE642508A (fr)
BE637950A (fr)
BE661759A (fr)
BE642104A (fr)
BE661205A (fr)
BE432268A (fr)
BE637777A (fr)
BE642212A (fr)
BE664955A (fr)
BE518974A (fr)
BE554195A (fr)
BE642243A (fr)
BE564626A (fr)
BE584699A (fr)
BE603534A (fr)
BE610935A (fr)
BE613833A (fr)
BE642316A (fr)
BE642367A (fr)
BE642470A (fr)
BE642654A (fr)

Legal Events

Date Code Title Description
CL Concession to grant licences